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Abstract
 
Leishmania
 
, a protozoan parasite, lives and multiplies as amastigote within macrophages. It is
proposed that the macrophage expressed CD40 interacts with CD40 ligand on T cells to in-
duce IFN-
 
 
 
, a Th1-type cytokine that restricts the amastigote growth. Here, we demonstrate
that CD40 cross-linking early after infection resulted in inducible nitric oxide synthetase type-2
(iNOS2) induction and iNOS2-dependent amastigote elimination. Although CD40 expression
remained unaltered on 
 
L. major
 
–infected macrophages, delay in the treatment of macrophages
or of mice with anti-CD40 antibody resulted in significant reduction in iNOS2 expression and
leishmanicidal function suggesting impaired CD40 signaling in 
 
Leishmania
 
 infection. The inhi-
bition of CD40-induced iNOS2 expression by SB203580, a p38-mitogen activated protein ki-
nase (p38MAPK)-specific inhibitor, and the reversal of the inhibition by anisomycin, a
p38MAPK activator, suggested a crucial role of p38MAPK in CD40 signaling. Indeed, the
CD40-induced p38MAPK phosphorylation, iNOS2 expression and anti-leishmanial function
were impaired in 
 
Leishmania
 
-infected macrophages but were restored by anisomycin. Anisomy-
cin’s effects were reversed by SB203580 emphasizing the role of p38MAPK in CD40-induced
iNOS2-dependent leishmanicidal function. Anisomycin administration in 
 
L. major
 
–infected
BALB/c mice resulted in significant reduction in the parasite load and established a host-pro-
tective Th1-type memory response. Also implicated in these findings is a scientific rationale to
define novel anti-parasite drug targets and to bypass the problem of drug resistance.
 
Key words: Leishmaniasis • immune evasion mechanism • CD40 signaling • p38MAPK • 
T cell memory
 
Introduction
 
Macrophages are the primary target cells for 
 
Leishmania ma-
jor
 
, the causative agent of the disease cutaneous leishmania-
sis. As activated macrophages eliminate the intracellular
amastigotes (1) and play a crucial role in the initiation and
regulation of host-protective anti-leishmanial T cell re-
sponse, the parasite deploys different immune evasion strat-
egies to survive within the macrophages (2). Categorically,
 
the strategies include direct interference with IFN-
 
 
 
–
mediated macrophage activation (3) and indirect interference
with macrophage activation by skewing the T-helper (Th)
cells to Th2 type, the disease-promoting Th subset that
suppresses the host-protective Th1 subset (4). It was pro-
posed that the interaction between CD40, a costimulatory
molecule expressed on macrophages, B cells, and dendritic
cells (5), and its ligand, CD40 ligand (CD154) on T cells
(6) results in Th subset skewing. The CD40-deficient mice
develop a Th2-skewed response and are susceptible to
 
Leishmania
 
 infection (7). The susceptibility to 
 
Leishmania
 
infection can be prevented by IL-12 administration in these
mice suggesting that CD40–CD154 interaction is required
for the production of IL-12, which polarizes the Th cells to
Th1 type (7, 8). Thus, the host-protective function of
CD40 was attributed to setting a Th1 bias (7–9). However,
these reports (7–9) neither explain the mechanism of the
failure of CD40 to prevent the progression of the disease in
susceptible mouse strains nor do they implicate modulation
of CD40 effector functions in macrophages as the parasite’s
immune evasion strategy. Therefore, we tested whether or
not CD40 signaling alone results in 
 
Leishmania
 
 killing in
macrophages. We have also studied the regulation of CD40
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signaling in 
 
Leishmania
 
-infected macrophages to explore
the nature of host-pathogen interaction and finally, based
on these experiments; we have tested whether or not a
pharmacological manipulation of CD40 signaling results in
a host-protective immune response.
 
Materials and Methods
 
Leishmania major and Infection of Animals.
 
BALB/c mice
were infected subcutaneously with 2 
 
 
 
 10
 
6
 
 
 
Leishmania major
 
(MHOM/Su73/5ASKH) promastigotes in saline (25 
 
 
 
l). The
disease was scored by measuring the footpad swelling by a digital
micrometer (Mitituyo) and by limiting dilution analysis of para-
site burden (10). In some experiments, BALB/c mice were
primed with 5 
 
 
 
 10
 
2
 
 promastigotes with or without anisomycin.
 
Reagents.
 
AMT, anisomycin, and SB203580 were procured
from Sigma-Aldrich. The FITC and PE-labeled anti-CD40 and
control isotypes, the purified anti-inducible nitric oxide syn-
thetase type-2 (iNOS2) antibodies and the cytokine Opt-EIA kits
were procured from BD Biosciences. Anti-CD40 antibody for
macrophage activation and Western blotting was purified from a
hybridoma (clone 3/23; kindly gifted by Dr. Gerry Klaus, Na-
tional Institute of Medical Research, London, UK) secreting the
antibody (11) by using a protein G–coupled sepharose affinity
column (Amersham Biosciences).
 
Leishmania Infection of Macrophages.
 
Thioglycolate-elicited
peritoneal macrophages from BALB/c mice were infected with
 
Leishmania
 
 promastigotes at a ratio of 1:10 for 6 h (10). The extra-
cellular parasites were washed out and the macrophages were cul-
tured with or without anti-CD40 antibody and anisomycin or
SB203580 treatment at the indicated doses for 72 h. The macro-
phages were then fixed, Giemsa-stained, and counted to calculate
the number of amastigotes per 100 macrophages (10).
 
CD40-induced Nitrite Production by Leishmania-infected and Unin-
fected Macrophages.
 
BALB/c-derived peritoneal macrophages
(5 
 
 
 
 10
 
5
 
 cells/ ml in IMDM), uninfected or 
 
Leishmania
 
-infected,
were treated with the anti-CD40 antibody (10 
 
 
 
g/ml) for 48 h.
The culture supernatants were collected. The nitrite concentra-
tion was measured by Griess reagent (ICN Biomedicals) follow-
ing Soong et al. (9)
 
.
RT-PCR for Analyzing iNOS2 and CD40 Expression.
 
BALB/
c-derived peritoneal macrophages, uninfected or 
 
Leishmania
 
-in-
fected, were treated with the anti-CD40 antibody or anisomycin
in presence or absence of SB203580 for 6 h. Total RNA was ex-
tracted using TRIZOL (Life Technologies). For cDNA synthesis,
1 
 
 
 
g of total RNA from each sample was incubated with random
primer, 0.1 M dithiothreitol, 500 
 
 
 
M dNTPs, 40 U RNase inhib-
itor, and 1 
 
 
 
l (200 U) of MMLV-reverse transcriptase (Life Tech-
nologies). Samples were then incubated at 37
 
 
 
C for 1 h followed
by 5 min incubation at 95
 
 
 
C. cDNA from each sample was ampli-
fied with Taq DNA Polymerase (GIBCO BRL) in 50 
 
 
 
l under
the following conditions: 95
 
 
 
C for 2 min, 94
 
 
 
C 1 min, 65
 
 
 
C for 1
min, and 72
 
 
 
C for 1 min for a total of 35 cycles. Specific primers
(GenoMechanix) were designed to amplify the mouse CD40
(sense: 5
 
 
 
-TCCCTGCCCAGTCGGCTTCT-3
 
 
 
; antisense: 5
 
 
 
-
CTGTCTTGGCTCATCTCAAA-3
 
 
 
) and iNOS2-coding re-
gions (sense: 5
 
 
 
AGCTCCTCCCAGGACCACAC-3
 
 
 
; antisense:
5
 
 
 
 ACGCTGAGTACCTCATTGGC 3
 
 
 
). Each sample was am-
plified for mouse DHFR to ensure equal cDNA input.
 
Preparation of Cell Lysates and Western Blot for iNOS2 and p38-
Mitogen-activated Protein Kinase.
 
Cell lysates were prepared as de-
scribed earlier (12). Macrophages (1–2 
 
 
 
 10
 
7
 
/ sample) were
 
washed twice with ice-cold TBS (25 mM Tris-HCl, pH 7.4, 150
mM NaCl, and 100 mM Na-ortho-vanadate) and harvested. The
cells were lysed in lysis buffer (20 mM HEPES, 25% glycerol,
0.42 M NaCl, 1.5 mM MgCl
 
2,
 
 0.2 mM EDTA, 0.5 mM DTT,
and 50 
 
 
 
g each of leupeptin, aprotinin, and PMSF) by incubation
on ice for 30 min. Lysates were centrifuged (13,000 rpm; 30 min).
The supernatants were collected and the protein contents were
determined by using the Bradford reagents (Bio-Rad Laborato-
ries). Obtained samples were boiled for five minutes in Laemmli
sample buffer, electrophoresed on 10% SDS-polyacrylamide, and
transferred to the nitrocellulose using a trans-blot system (Hoeffer
Scientific). The nitrocellulose filter was washed, blocked with 5%
BSA for 1 h at room temperature, and incubated with anti-
iNOS2 antibody for 1 h. The blots were washed and incubated
with an HRP-conjugated secondary antibody (1:1,000 in wash
buffer containing 1% BSA) for 1 h at room temperature. Immu-
noreactive bands were visualized by the enhanced chemilumines-
cence system (Amersham Biosciences). Each sample was blotted
with anti-
 
 
 
-actin antibody (Santa Cruz Biotechnology, Inc.) to
ensure equal input of protein samples onto the gel.
Similar protocols were followed for detecting the phos-
pho-  and dephospho–p38-mitogen-activated protein kinase
(p38MAPK) in differently treated macrophages using phospho or
dephospho-p38MAPK-specific antibodies. The same blot was
used to probe for phospho-p38AMPK and reprobe for dephos-
pho-p38MAPK.
 
CD40 Expression by Flow Cytometry.
 
BALB/c-derived mac-
rophages, uninfected or 
 
L. major-
 
infected, as described above,
were stained with PE-labeled anti-CD40 antibody. The cells
were analyzed by a FACSVantage™ flow cytometer (Becton
Dickinson).
 
Cytokine ELISA.
 
CD4
 
 
 
 T cells from the lymph nodes of the
mice, naive or treated, were incubated with anti-CD3 (1 
 
 
 
g/ml)
and anti-CD28 (5 
 
 
 
g/ml) antibodies for 72 h. The culture super-
natants were assayed for the cytokines by using Opt-EIA kits fol-
lowing manufacturer’s instructions.
 
Statistical Analysis.
 
The in vitro cultures were in triplicates
and a minimum of five mice was used per group for in vivo ex-
periments. The data, presented as mean 
 
 
 
 standard deviation, is
from one experiment which was performed at least three times.
Student’s 
 
t
 
 test was employed to assess the significance of the
differences between the mean values of control and experimen-
tal groups.
 
Results
 
CD40 Signaling Results in iNOS2-dependent Killing of
Amastigotes in Early-infected but Not in Late-infected Macro-
phages.
 
The anti-CD40 antibody treatment of the mac-
rophages 6 h after infection resulted in significant reduction
in percent infection and in the amastigote number per hun-
dred infected macrophages (Fig. 1 A; P 
 
  
 
0.01) suggesting
that the CD40 signal regulates amastigote survival. AMT, an
iNOS2 inhibitor (13), inhibited the CD40-induced anti-
leishmanial function suggesting an iNOS2-dependent anti-
leishmanial function of CD40 (Fig. 1, A–C). It was observed
by RT-PCR and Western blot that the anti-CD40 antibody
treatment of macrophages resulted in iNOS2 induction in a
dose- and time-dependent manner (Fig. 1, B and C).
As 
 
Leishmania
 
 suppresses host-protective immune re-
sponse (2), we tested if the anti-leishmanial function ofT
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CD40 persists in late-infected macrophages. Therefore, the
macrophages were infected for 12 to 72 h before they were
treated with the anti-CD40 antibody for another 24 h. It
was observed that the anti-CD40 antibody treatment re-
sulted in 67% decrease in the number of amastigotes per
100 12-h infected macrophages as compared with the 22–
38% decrease in 24 to 72 h infected macrophages (Fig. 1
D) implying a significant impairment in CD40-induced
anti-leishmanial function in macrophages parasitized for
more than 12 h. The decrease in anti-leishmanial function
was possibly due to impaired CD40-induced iNOS2 ex-
pression (Fig. 1 E), as confirmed by the analysis in the ex-
ponential phase of PCR amplification (Fig. 1 F). Corrobo-
rating to the RT-PCR data, the CD40-induced nitrite
production was significantly reduced in the late-infected
macrophages (Fig. 1 G).
 
Leishmania Infection of Macrophages Does Not Down-regulate
CD40 Expression.
 
The interference with the CD40-
induced anti-leishmanial activity might be executed by
 
two different mechanisms: down-regulated CD40 expres-
sion resulting in a quantitative decrease in CD40 signaling
or impaired CD40 signaling despite unaltered CD40 ex-
pression. Therefore, we tested whether or not 
 
Leishmania
 
infection resulted in reduced CD40 expression. We ob-
served that in striking contrast with the deregulated
expression of other costimulatory molecules like CD80 or
ICAM-1 (14), CD40 expression was not significantly al-
tered on 
 
Leishmania
 
-infected macrophages (Fig. 2 A).
Therefore, the loss of anti-leishmanial function in late-
infected macrophages was perhaps due to impaired CD40
signaling.
 
p38MAPK Plays an Important Role in CD40 Signaling in
Macrophages.
 
As 
 
Leishmania
 
 infection is proposed to alter
LPS-induced p38MAPK activity (15), we tested whether
or not CD40 signals through p38MAPK in macrophages
and if it does, whether or not the regulation of p38MAPK
activity by its pharmacological inhibitor, SB203580
(16), or activator, anisomycin (17), modulates the CD40-
Figure 1. CD40 stimulation results in the induction of iNOS2 expression and iNOS2-dependent amastigote elimination. (A) CD40 induces leish-
manicidal activity in BALB/c-derived peritoneal macrophages. The macrophages were infected with L. major promastigotes at a ratio of 1:10 for 6 h at
33 C and anti-CD40 antibody (clone 3/23; 2  g/ml), with or without AMT, were added to the cultures. After 72 h, the macrophages were fixed, Gi-
emsa-stained, and the percent-infected macrophages and the number of amastigotes per 100 infected macrophages were counted under a microscope.
Values are expressed in mean   SD. Anti-CD40 antibody treatment reduced infection significantly (*, P   0.01). (B) CD40 induces iNOS2 expression.
The BALB/c-derived peritoneal macrophages were incubated with different doses of the anti-CD40 antibody as indicated. RNA was extracted 3 h after
stimulation and the RT-PCR for iNOS2 expression was performed as described in Materials and Methods. The density units shown in the bar diagram
are arbitrary units obtained from the densitometric analysis using the Quantity-One software. (C) Time-kinetics of CD40-induced iNOS2 expression.
Macrophages were stimulated with anti-CD40 antibody (2  g/ml) as described above. Cells were lysed at different time points after anti-CD40 antibody
treatment to obtain RNA (RT-PCR) or protein (WB). RNA was used for iNOS2 RT-PCR and the protein was used for iNOS2 Western blot (WB)
analysis as described in Materials and Methods. (D) Delay in anti-CD40 antibody treatment results in the loss of its anti-leishmanial function. BALB/c-
derived macrophages were infected with promastigotes at a 1:10 ratio in 16-well tissue culture slides for the indicated period. The cultures were treated
with anti-CD40 or left untreated for another 24 h. The macrophages were fixed, Giemsa-stained, and 500 cells were counted as described under Materi-
als and Methods. Values are expressed in mean   SD (*, P   0.01). (E) iNOS2 induction by CD40 is impaired in Leishmania-infected macrophages.
Macrophages were cultured uninfected or Leishmania-infected for 72 h, followed by anti-CD40 antibody (2  g/ml) treatment for 3 h. RNA was isolated
from these macrophages and RT-PCR for DHFR and iNOS was performed. (F) RNA was isolated from the macrophages as described in the panel (E).
RT-PCR for iNOS2 was performed for the indicated cycles and densitometric analysis was done. (G) CD40-induced nitrite production is impaired in
Leishmania-infected macrophages. The macrophage cultures, as stated above, were maintained for 72 h. Culture supernatants were collected and nitrite
concentration was measured using Griess reagent and calculated by comparison to NaNO2 as a standard. The data (mean   SD) showing significant re-
duction of CD40-induced nitrite production (*, P   0.005) in Leishmania infection is from one of three experiments.T
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induced leishmanicidal activity. It was observed that
SB203580 prevented CD40-induced p38MAPK phos-
phorylation and iNOS2 expression while anisomycin in-
duced p38MAPK phosphorylation and iNOS2 expression
in a dose-dependent manner (Fig. 2, B and C). Together
with these observations, the reversal of SB203580-medi-
ated inhibition of CD40-induced iNOS2 expression
by anisomycin (Fig. 2 C) suggested that CD40 sig-
nals  through p38MAPK in macrophages regulating
iNOS2 expression and that anisomycin directly activates
p38MAPK, as anisomycin reverses the inhibitory activities
of SB203580.
 
CD40 Signaling Is Impaired in Leishmania-infected Macro-
phages but Rescued by Anisomycin.
 
We tested whether or
not CD40 signaling through p38MAPK is impaired in late-
infected (72 h infected) macrophages and if it is, whether or
not anisomycin restored CD40 signaling. It was observed
that anti-CD40-induced p38MAPK phosphorylation (Fig.
3 A) and iNOS2 expression (Fig. 3 B) were impaired in
the late-infected macrophages. Treatment of these macro-
Figure 2. CD40 signals through
p38MAPK in macrophages and its expres-
sion remain unchanged in Leishmania-
infected macrophages. (A) CD40 expres-
sion is not down-regulated in the Leishma-
nia-infected macrophages. BALB/c-derived
macrophages were cultured uninfected or
Leishmania-infected for 72 h. The macro-
phages were stained with anti-CD40-PE
antibody and CD40 expression was ana-
lyzed with a FACSVantage™ flow cytome-
ter. CD40 expression by RT-PCR was per-
formed as described in Materials and Methods.
(B) Anisomycin (Aniso), a p38MAPK acti-
vator, and CD40 cross-linking induces
p38MAPK phosphorylation and SB203580
(SB), an inhibitor of p38MAPK, inhibits
the CD40-triggered p38MAPK phosphor-
ylation. Macrophages were stimulated with
anti-CD40 (2  g/ml) alone or with the in-
dicated doses of SB203580 or anisomycin
for 15 min. Cell extracts were prepared and
Western blot was performed to detect
phospho- and dephospho-p38MAPK as de-
scribed earlier. (C) SB203580 inhibits while
anisomycin induces the CD40-triggered
iNOS2 expression. RNA was isolated from
BALB/c macrophages, which were stimu-
lated with anti-CD40 antibody alone (2
 g/ml) or with the indicated doses of SB203580 or anisomycin alone or in combination, as indicated, for 3 h and RT-PCR for iNOS2 message was
performed as described earlier. The data shown is from one of three individual experiments.
Figure 3. CD40-induced p38MAPK phosphorylation, iNOS2 induction, and anti-leishmanial function are impaired during Leishmania infection but
restored by anisomycin. The uninfected and the L. major–infected macrophages, treated as indicated, were lysed to obtain protein, for studying
p38MAPK phosphorylation (A) or RNA, for studying iNOS2 expression (B), as described in Materials and Methods. In some experiments (C), mac-
rophages were treated with anti-CD40 antibody either at the beginning of infection (CD40-E) with or without SB203580 or 72 h after infection (CD40-L)
with or without anisomycin. Macrophages were fixed, stained and counted to record the number amastigotes per 100 macrophages. The data (mean  
SD) showed that anisomycin rescued the CD40-induced anti-leishmanial effect (CD40-L An) significantly (*, P   0.01).T
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phages with anisomycin alone or in combination with anti-
CD40 resulted in the restoration of p38MAPK phosphory-
lation and iNOS2 expression (Fig. 3, A and B). Similarly,
CD40-induced anti-leishmanial function was significantly
reduced in late-infected macrophages but rescued by aniso-
mycin (P   0.01; Fig. 3 C). Therefore, these results indi-
cate that Leishmania interrupts the CD40 signaling by in-
hibiting p38MAPK phosphorylation. As anisomycin does
not kill promastigotes (data not shown) and, as predicted by
docking simulation, fits into p38MAPK (unpublished data),
it is suggested that the anti-leishmanial effect of anisomycin
is through p38MAPK.
Anisomycin Retains Its Anti-leishmanial Activity In Vivo and
Establishes a Host-protective Memory T Cell Response. As
anisomycin rescued the CD40 signaling defect in vitro,
we administered this drug in Leishmania-infected BALB/c
mice to test its therapeutic potential. Four groups of L.
major–infected mice were either left untreated or treated
with anti-CD40 antibody alone from the beginning or 7 d
after infection or with the antibody plus anisomycin 7 d
after infection. It was observed that the delay in begin-
ning the treatment with anti-CD40 antibody alone failed
to reduce the infection but when treated in combination
with anisomycin, the disease, as assessed by foot-pad
swelling and parasite load, was significantly less severe
(P   0.001) compared with controls (Fig. 4, A and B). A
comparison between the cytokine profiles in the aniso-
mycin-treated and control mice demonstrated that IFN- 
was much higher in the former whereas IL-4 was higher
in the latter groups (P   0.01; Fig. 4 C). The observation
suggested that the anti-leishmanial activity of anisomycin
was associated with the Th subset skewing. Importantly,
the mice, which were primed with anisomycin plus ultra-
low dose of L. major, developed significantly less severe
disease during reinfection as compared with the control
mice (P   0.001; Fig. 5 A). Restimulation of the T cells
from the draining lymph nodes of these mice resulted in
more IFN-  and less IL-4 production in the primed/ani-
somycin-treated group than the untreated group (Fig. 5
B). Although we do not know whether or not anisomy-
cin treatment in vivo established the host-protective
memory by working on T cells or macrophages or both,
nevertheless, our results suggest that p38MAPK plays an
important role in establishing host-protective memory T
cell response.
Figure 4. Anisomycin treatment results in significant decrease in infection (A and B) and is associated with a Th1-type response (C). BALB/c mice
were infected with L. major promastigotes (2   106) and were treated either at the beginning of infection with saline (Control) or anti-CD40 (CD40-E)
or 7 d after infection with anti-CD40 antibody alone (CD40-L) or in combination with anisomycin (Aniso). The footpad swelling was measured weekly
(A) and the parasite load was measured on day 35 post-infection (B). CD4  T cells from lymph nodes of naive or infected mice treated with saline, anti-
CD40 antibody or anisomycin were stimulated in vitro with anti-CD3   anti-CD28 for 36 h. The cell culture supernatants were assayed for IL-4 and
IFN-  (C). The data (mean   SD) represents one of three individual experiments. Anti-CD40 or anisomycin treatment reduced infection significantly
(*, P   0.001), decreased IL-4 and increased IFN-  production significantly (P   0.01).
Figure 5. Priming of BALB/c mice with ultra-low dose of L. major
plus anisomycin establishes a host-protective Th1-type memory response.
(A) BALB/c mice, primed with 5   102 Leishmania promastigotes alone
(Circle) or with anisomycin (inverted triangle), showed no demonstrable
infection after 6 wk (Primary). The mice were then challenged with L.
major promastigotes (2   106). The net footpad swelling in the control
(open bar) or anisomycin-treated (hatched bar) mice was measured 6 wk
after infection (Secondary). Limiting dilution assay assessed parasite load
in the footpad (Inset). Values are expressed in mean   SD. Anisomycin
priming reduced the infection significantly (*, P   0.001). (B) CD4  T
cells from popliteal lymph nodes of the control (open bar) or anisomycin-
treated (hatched bar) mice were stimulated with anti-CD3 anti-CD28
for 36 h. IL-4 and IFN-  were measured in the supernatants by ELISA.
The data (mean   SD) representing one of three experiments shows that
anisomycin priming reduced IL-4 production but increased IFN-  pro-
duction significantly (*, P   0.005).T
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Discussion
Successful invasion and survival of a parasite within an
immunocompetent host depends on its ability to adapt itself
to the anti-parasitic microenvironment and to subvert the
host’s immune response (2). Our data reveals a novel fact
that Leishmania impairs the CD40 effector functions by in-
terrupting the CD40 signaling through p38MAPK in mac-
rophages. The impairment in p38MAPK in Leishmania-
infected macrophages could be due to the inhibition of PI-3
kinase (6), ras-raf-rac system (18), or protein kinase C (19)
that are known to be involved in CD40 signaling and
p38MAPK phosphorylation. The signaling intermediates
upstream of p38MAPK could be impaired by the parasite
directly, where a parasite product interacts with one or
more of these proteins (20) to inhibit phosphorylation or in-
crease dephosphorylation (21) or, indirectly, by inducing a
host-derived factor that may act in an autocrine manner to
incapacitate the CD40 signaling. For example, a selective
impairment of LPS-activated protein kinase C isotypes in
Leishmania donovani–infected macrophages by leishmanial li-
pophosphoglycan and host-derived IL-10 is reported (19).
We have observed that IL-10 impairs CD40-triggered
iNOS2 expression and anti-leishmanial function (unpub-
lished data). As CD40-CD40 ligand (CD154) interaction
generates CD40 signals that play important roles in modu-
lating Th1-dependent anti-leishmanial response (7–9), we
have studied the effect of Leishmania infection on CD40 sig-
naling in macrophages and the involvement of p38MAPK
in the establishment of anti-leishmanial immune response.
Our observations indicate that as an immune evasion strat-
egy and for establishing infection, Leishmania inhibits
CD40-triggered p38MAPK signaling. On the other hand,
anisomycin’s ability to restore CD40 signaling and eliminate
amastigotes not only highlights the susceptibility of amasti-
gotes to killing after p38MAPK activation but also suggests a
potential use of anisomycin as an anti-leishmanial drug.
The two most important problems in designing an anti-
parasitic drug are defining the target and the development
of drug-resistance by the parasite. The current study sug-
gests a strategy that addresses both the problems. First, since
a parasite impairs the functions of the host cell proteins em-
ployed to eliminate the parasite, a drug target can in princi-
ple be identified by tracking the host cell proteins impaired
by the parasite. An activator of such a crucial host cell pro-
tein, like anisomycin for the p38MAPK in the present re-
port, may therefore be considered as a drug candidate. Sec-
ond, the parasite biomolecules, which are absent in the
host, are considered as drug targets. As these drugs inhibit
the activities of the target parasite molecules, they exert a
selection pressure on the parasite resulting in the emer-
gence of drug resistance (22). As anisomycin controls the
parasite by restoring the host immune system, the emer-
gence of drug-resistance can be avoided. Furthermore, the
amelioration of the disease is accompanied by Th1-pre-
dominance suggesting that the anisomycin treatment gen-
erates a bystander host-protective Th cell memory render-
ing the host relatively resistant to reinfection.
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